The results may limit the utility of anti-SARS-CoV-2 IgA and IgM in clinical practice in tropical areas where dengue is co-epidemic, while anti-SARS-CoV-2 IgG may alternatively be used. The gene discussed is CD79A; the disease is dengue disease.